Melior Pharmaceuticals I, Inc.;Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
发明人:
Reaume, Andrew G.,Cong, Weina,Greenway, Frank,Coulter, Ann
申请号：
AU2018250795
公开号：
AU2018250795A1
申请日:
2018.04.09
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
The present disclosure provides compositions comprising a lyn kinase activator and TRPM8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels； treating metabolic syndrome, Syndrome X, obesity, prediabetes, type II diabetes, type I diabetes； treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, or pancreatitis； inducing the beiging of adipocytes； and preventing pancreatic beta cell degeneration.
